Serum levels of endothelial monocyte activating polypeptide II in type 1 diabetes patients with microangyopathy and arterial hypertention.
Aim To determine the serum level of EMAP II in type 1 diabetic patients with microangyopathy and arterial hypertention. Materials and methods We examined 23 type 1 diabetic patient with microangyopathy and arterial hypertention, 10 type 1 diabetic patient with microangyopathy without hypertention and 28 control subjects. Serum levels of EMAP II were determined by immunoenzyme assay. The data were presented as means+ SD. Results. We found an increased serum level of EMAP II in type 1 diabetic patients with microangyopathy and arterial hypertention compared to control group (5,23+ 1,66 ng/ml and 1,25+ 0,76 ng/ml respectively, r<0,01) and in type 1 diabetic patients with microangyopathy and arterial hypertension compared to group without hypertension (5,23+ 1,66 ng/ml and 3,63+ 1,9 ng/ml respectively, r<0,01) Also, the level of EMAP II correlated with key markers of carbohydrate and lipid metabolism, inverse correlated with endothelium dependent dilatation (p<0,05) Conclusion The revealed change of EMAP II could reflect an endothelial dysfunction in patients with type 1 diabetes with microangyopathy and arterial hypertension. Arterial hypertension, hyperglycemia, dyslipidemia appears to be significant factor to contributing elevation of EMAP II. Keywords Endothelial monocyte activating polypeptide II, endothelial dysfunction, type 1 diabetes, arterial hypertension.